Dr. Princess Imoukhuede from University of Illinois has developed a new quantitative receptor measurement approach for examining glioblastomas (GBM) heterogeneity. This approach is a paradigm shift in single-cell technologies: from gene-centric to proteomics. It provides never-before-seen insight into GBM heterogeneity that will ultimately enable more effective cancer treatment. It is a sensitive, quantitative approach that enables high-throughput measurements.